Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $30.58, but opened at $33.65. Nanobiotix shares last traded at $33.04, with a volume of 8,075 shares changing hands.

Analysts Set New Price Targets

A number of research firms recently weighed in on NBTX. Guggenheim increased their price objective on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. TD Cowen started coverage on Nanobiotix in a research note on Friday, February 6th. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.00.

Nanobiotix Stock Up 10.2%

The business’s fifty day moving average is $23.21 and its 200 day moving average is $19.81.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors have recently bought and sold shares of NBTX. Royal Bank of Canada lifted its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of Nanobiotix in the third quarter worth approximately $101,000. Marshall Wace LLP purchased a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter worth approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.